ArticleCancer science2024
Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered.
Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gender-neutral vs. gender-specific strategies in school-based HPV vaccination programs: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Web-Based Video Intervention and Associated Factors for the Uptake of the Catch-Up Human Papillomavirus Vaccination in Japan: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Survey to Document the Adverse Reactions After Human Papillomavirus Vaccination Among Japanese Female Youth at a University.The journal of obstetrics and gynaecology research · 2026Article
- Psychosocial Burden of Women With Cervical Intraepithelial Neoplasia in Japan: Results of A Web-Based Survey.The journal of obstetrics and gynaecology research · 2026Observational
- The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study.BMC public health · 2025Article
- Comparative Cytokine and Histology Studies on HPV and Other Viral Vaccinations: No Pathogenicity of HPV Vaccine Adjuvants.Cancer science · 2025Article
- The effects of human papillomavirus vaccination in Japan.Human vaccines & immunotherapeutics · 2025Article
- Overcoming HPV Vaccine Hesitancy in Japan: A Narrative Review of Safety Evidence, Risk Communication, and Policy Approaches.Vaccines · 2025Review
- Gender-neutral human papillomavirus vaccination: an equitable and cost-effective public health investment.Frontiers in public health · 2025Article
- Unlocking Japan's cervical cancer prevention deadlock.Cancer science · 2024Article
- Article
- Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered.Cancer science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Japan has a particularly critical situation surrounding its collapsed HPV vaccination program for preventing HPV-caused cervical cancers, a problem exacerbated by the lack of a national immunization database. We have determined the year-to-year HPV vaccination uptake by Japanese females and analyzed by birth fiscal year (FY) the monthly number of people receiving initial HPV vaccination. Our analysis covers the period from the start of public subsidies in 2010 to September 2023, using data provided by local governments. We calculated the cumulative number of monthly immunizations for those unimmunized as of April (the beginning of each vaccination year). The monthly number of initial HPV vaccinations was highest in August for every FY from FY 2010 to FY 2023; a second vaccination peak tended to occur in March when the vaccination year ended. The highest number of August vaccinations occurred in FY 2011, followed (in order) by 2012, 2021, 2022, 2023, and 2013. In Japan's ongoing catch-up vaccination program for young women, the monthly number of vaccinations increased in August 2022 but then slowed the following year. After FY 2021, the cumulative vaccination coverage of subjects unvaccinated at the beginning of the vaccination year but subsequently covered by routine immunizations was slightly improved. FY 2021 was when the governmental recommendations for HPV vaccination were resumed. More recent vaccination rates are considerably lower than those in FY 2011-2012 when vaccinations were first fully endorsed. Paralyzing HPV vaccination hesitancy, which began in FY 2013, will linger in Japan in FY 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.